A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)

Open

Phase

Abbreviated Title

Phase II Rand Trial of Radium-223 Dichloride and Cabozantinib in Pts with Adv Renal Cell Carcinoma with Bone Mets (RadiCal)

Activated

12/13/2019

Eligibility Criteria Expand/Collapse

Please see eligibility criteria in protocol on www.CTSU.org

Publication Information Expand/Collapse

2022

A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)

R McKay;H Jacene;P Atherton;V Marcotte;A Ajmera;S Baghaie;J Koball;T Zemla;R Chen;A Choudhury;J Lang;S Cole;M Parikh;T Al Baghdadi;Y Kwok;A Tan;H Beltran;D George;M Morris;T Choueiri International Kidney Cancer Symposium (November 4-5, 2022, Austin, TX), TIPS, Poster Board F1 Abstract 49